Global Anterior Uveitis Treatment Market by Treatments (Corticosteroids, Cycloplegic Agents, Anti-TNF Agents, and Immunosuppressants), Distribution Channels (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies), and Regions (Asia Pacific, North America, Europe, Latin America, and Middle East & Africa) Forecast, 2021-2028
The global anterior uveitis treatment market is anticipated to expand at a substantial CAGR during forecast period, between 2021 and 2028. The growth of the market is attributed to Increasing prevalence of anterior uveitis across the globe.
Uveitis is a group of inflammatory diseases that destroys eye tissues and causes uvea (middle layer of eye) swelling. These diseases can sometimes lead to severe vision loss. The various types of uveitis are posterior uveitis, anterior uveitis, panuveitis uveitis, and intermediate uveitis. Some diseases such as AIDS, multiple sclerosis, rheumatoid arthritis, tuberculosis, and ulcerative colitis increases the risk of uveitis.
Anterior uveitis affects the front, colored part of the eye, the iris and hence, it is also known as iritis. It is commonly seen in young and middle-aged people. The common symptoms of anterior uveitis include pain, photophobia, redness, decreased vision, and lacrimation. These symptoms if not treated can result in permanent blindness.
Market Trends, Drivers, Restraints, and Opportunities:
- Favorable government regulations and growing geriatric population is estimated to contribute to the market growth during the forecast period.
- Ongoing developments in the applications of products and treatment modalities are expected to provide long term opportunity for the market growth.
- Factors such as lack of knowledge about eye-related diseases, steep prices of medications, unavailability of health insurance in some developing countries, and side effects of medication including watery eyes and irritation are expected to hinder the market growth.
Scope of the report:
The report on anterior uveitis treatment market includes an assessment of the market, size, share, trends, segments, and regional markets. Overview and dynamics have been included in the report.
|
Attributes |
Details |
|
Base Year |
2020 |
|
Historic Data |
2018–2019 |
|
Forecast Period |
2021–2028 |
|
Regional Scope |
Asia Pacific, North America, Europe, Latin America, and Middle East & Africa |
|
Report Coverage |
Market scope, analysis, share, competitive analysis, growth facts, restraints, opportunities and revenue forecast |
Anterior Uveitis Treatment Market Segment Insights:
Several advantages of corticosteroids over other treatments are driving the segmental growth
Based on treatment types, the global anterior uveitis treatment market can be bifurcated into corticosteroids, cycloplegic agents, anti-tnf agents, and immunosuppressants. The corticosteroids segment held a significant market share, as they are first line therapies for anterior uveitis. Corticosteroids are inexpensive, potent, and act fast. Moreover, they may be administered systematically (oral, intramuscular or intravenous routes), topically, or through periocular injections. Furthermore, corticosteroids are mostly preferred over biologics. Hence, the segment is expected to expand at a substantial CAGR during the forecast period.
Online pharmacies segment is expected to register higher CAGR during the forecast period
On the basis of distribution channels, the market can be segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Online pharmacies segment is expected to expand at a significant CAGR during the forecast period. The growth of the segment is attributed to the increasing popularity of online pharmacies owing to the advantages such as convenience, time saving, low price, and insights on the usage of drugs. Moreover, increasing number of Internet users and higher dependency on online goods are expected to boost the market growth during the forecast period.
North America is expected to account for a significant share of the global market
Based on regions, the global anterior uveitis treatment market is fragmented into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. North America held the highest market share and is projected to expand at a moderate CAGR during the forecast period. Growing prevalence of the diseases in the US and presence of key market players in this region is expected to contribute to the regional growth during the forecast period. Moreover, the approval of drugs and development of new methods such as step cell therapy for the treatment of anterior uveitis is driving the market growth across the region.
Segments
Segments Covered in the ReportThe global anterior uveitis treatment market has been divided based on treatment types, distribution channels, and regions.
By Treatment Types
- Corticosteroids
- Cycloplegic Agents
- Anti-TNF Agents
- Immunosuppressants
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- North America
- Europe
- Latin America
- Asia Pacific
- Middle East & Africa
- Santen Pharmaceutical Co. Ltd.
- AbbVie Inc.
- Novartis AG
- Eyegate Pharmaceuticals Inc.
- Aldeyra Therapeutics Inc.
- Aciont Inc.
- Clearside Biomedical Inc.
- Sirion Therapeutics Inc.
- Lux Biosciences Inc.
- Bausch & Lomb Incorporated
- UCB Biopharma S.P.R.L.
- EyePoint Pharmaceuticals Inc.
- Alimera Sciences Inc.
- Regeneron Pharmaceuticals
Competitive Landscape
Key players in the global anterior uveitis treatment market includes Santen Pharmaceutical Co., Ltd., AbbVie Inc., Novartis AG, Eyegate Pharmaceuticals, Inc., Aldeyra Therapeutics, Inc., Aciont Inc., Clearside Biomedical, Inc., Sirion Therapeutics, Inc., Lux Biosciences, Inc., Bausch & Lomb Incorporated, UCB Biopharma S.P.R.L., EyePoint Pharmaceuticals, Inc., Alimera Sciences Inc., and Regeneron Pharmaceuticals.
Collaborations, mergers, acquisitions, agreements, and partnerships are strategies adopted by these players to strengthen their geographical presence.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Anterior Uveitis Treatment Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Anterior Uveitis Treatment Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Anterior Uveitis Treatment Market - Supply Chain
4.5. Global Anterior Uveitis Treatment Market Forecast
4.5.1. Anterior Uveitis Treatment Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Anterior Uveitis Treatment Market Size (000’ Units) and Y-o-Y Growth
4.5.3. Anterior Uveitis Treatment Market Absolute $ Opportunity
5. Global Anterior Uveitis Treatment Market Analysis and Forecast by Types
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Types
5.2.2. Y-o-Y Growth Projections by Types
5.3. Anterior Uveitis Treatment Market Size and Volume Forecast by Types
5.3.1. Corticosteroids
5.3.2. Cycloplegic Agents
5.3.3. Anti-TNF Agents
5.3.4. Immunosuppressants
5.4. Absolute $ Opportunity Assessment by Types
5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global Anterior Uveitis Treatment Market Analysis and Forecast by Region
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Region
6.2.2. Y-o-Y Growth Projections by Region
6.3. Anterior Uveitis Treatment Market Size and Volume Forecast by Region
6.3.1. North America
6.3.2. Latin America
6.3.3. Europe
6.3.4. Asia Pacific
6.3.5. Middle East and Africa (MEA)
6.4. Absolute $ Opportunity Assessment by Region
6.5. Market Attractiveness/Growth Potential Analysis by Region
6.6. Global Anterior Uveitis Treatment Demand Share Forecast, 2019-2026
7. North America Anterior Uveitis Treatment Market Analysis and Forecast
7.1. Introduction
7.1.1. Basis Point Share (BPS) Analysis by Country
7.1.2. Y-o-Y Growth Projections by Country
7.2. North America Anterior Uveitis Treatment Market Size and Volume Forecast by Country
7.2.1. U.S.
7.2.2. Canada
7.3. Absolute $ Opportunity Assessment by Country
7.4. North America Anterior Uveitis Treatment Market Size and Volume Forecast by Types
7.4.1. Corticosteroids
7.4.2. Cycloplegic Agents
7.4.3. Anti-TNF Agents
7.4.4. Immunosuppressants
7.5. Basis Point Share (BPS) Analysis by Types
7.6. Y-o-Y Growth Projections by Types
7.7. Market Attractiveness/Growth Potential Analysis
7.7.1. By Country
7.7.2. By Product Type
7.7.3. By Application
7.8. North America Anterior Uveitis Treatment Demand Share Forecast, 2019-2026
8. Latin America Anterior Uveitis Treatment Market Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis by Country
8.1.2. Y-o-Y Growth Projections by Country
8.1.3. Latin America Average Pricing Analysis
8.2. Latin America Anterior Uveitis Treatment Market Size and Volume Forecast by Country
8.2.1. Brazil
8.2.2. Mexico
8.2.3. Rest of Latin America
8.3. Absolute $ Opportunity Assessment by Country
8.4. Latin America Anterior Uveitis Treatment Market Size and Volume Forecast by Types
8.4.1. Corticosteroids
8.4.2. Cycloplegic Agents
8.4.3. Anti-TNF Agents
8.4.4. Immunosuppressants
8.5. Basis Point Share (BPS) Analysis by Types
8.6. Y-o-Y Growth Projections by Types
8.7. Market Attractiveness/Growth Potential Analysis
8.7.1. By Country
8.7.2. By Product Type
8.7.3. By Application
8.8. Latin America Anterior Uveitis Treatment Demand Share Forecast, 2019-2026
9. Europe Anterior Uveitis Treatment Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.1.3. Europe Average Pricing Analysis
9.2. Europe Anterior Uveitis Treatment Market Size and Volume Forecast by Country
9.2.1. Germany
9.2.2. France
9.2.3. Italy
9.2.4. U.K.
9.2.5. Spain
9.2.6. Russia
9.2.7. Rest of Europe
9.3. Absolute $ Opportunity Assessment by Country
9.4. Europe Anterior Uveitis Treatment Market Size and Volume Forecast by Types
9.4.1. Corticosteroids
9.4.2. Cycloplegic Agents
9.4.3. Anti-TNF Agents
9.4.4. Immunosuppressants
9.5. Basis Point Share (BPS) Analysis by Types
9.6. Y-o-Y Growth Projections by Types
9.7. Market Attractiveness/Growth Potential Analysis
9.7.1. By Country
9.7.2. By Product Type
9.7.3. By Application
9.8. Europe Anterior Uveitis Treatment Demand Share Forecast, 2019-2026
10. Asia Pacific Anterior Uveitis Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Asia Pacific Average Pricing Analysis
10.2. Asia Pacific Anterior Uveitis Treatment Market Size and Volume Forecast by Country
10.2.1. China
10.2.2. Japan
10.2.3. South Korea
10.2.4. India
10.2.5. Australia
10.2.6. Rest of Asia Pacific (APAC)
10.3. Absolute $ Opportunity Assessment by Country
10.4. Asia Pacific Anterior Uveitis Treatment Market Size and Volume Forecast by Types
10.4.1. Corticosteroids
10.4.2. Cycloplegic Agents
10.4.3. Anti-TNF Agents
10.4.4. Immunosuppressants
10.5. Basis Point Share (BPS) Analysis by Types
10.6. Y-o-Y Growth Projections by Types
10.7. Market Attractiveness/Growth Potential Analysis
10.7.1. By Country
10.7.2. By Product Type
10.7.3. By Application
10.8. Asia Pacific Anterior Uveitis Treatment Demand Share Forecast, 2019-2026
11. Middle East & Africa Anterior Uveitis Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Middle East & Africa Average Pricing Analysis
11.2. Middle East & Africa Anterior Uveitis Treatment Market Size and Volume Forecast by Country
11.2.1. Saudi Arabia
11.2.2. South Africa
11.2.3. UAE
11.2.4. Rest of Middle East & Africa (MEA)
11.3. Absolute $ Opportunity Assessment by Country
11.4. Middle East & Africa Anterior Uveitis Treatment Market Size and Volume Forecast by Types
11.4.1. Corticosteroids
11.4.2. Cycloplegic Agents
11.4.3. Anti-TNF Agents
11.4.4. Immunosuppressants
11.5. Basis Point Share (BPS) Analysis by Types
11.6. Y-o-Y Growth Projections by Types
11.7. Market Attractiveness/Growth Potential Analysis
11.7.1. By Country
11.7.2. By Product Type
11.7.3. By Application
11.8. Middle East & Africa Anterior Uveitis Treatment Demand Share Forecast, 2019-2026
12. Competition Landscape
12.1. Global Anterior Uveitis Treatment Market: Market Share Analysis
12.2. Anterior Uveitis Treatment Distributors and Customers
12.3. Anterior Uveitis Treatment Market: Competitive Dashboard
12.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
12.4.1. Santen Pharmaceutical Co. Ltd.
12.4.2. AbbVie Inc.
12.4.3. Novartis AG
12.4.4. Eyegate Pharmaceuticals Inc.
12.4.5. Aldeyra Therapeutics Inc.
12.4.6. Aciont Inc.
12.4.7. Clearside Biomedical Inc.
12.4.8. Sirion Therapeut
2. Assumptions and Acronyms Used
3. Research Methodology
4. Anterior Uveitis Treatment Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Anterior Uveitis Treatment Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Anterior Uveitis Treatment Market - Supply Chain
4.5. Global Anterior Uveitis Treatment Market Forecast
4.5.1. Anterior Uveitis Treatment Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Anterior Uveitis Treatment Market Size (000’ Units) and Y-o-Y Growth
4.5.3. Anterior Uveitis Treatment Market Absolute $ Opportunity
5. Global Anterior Uveitis Treatment Market Analysis and Forecast by Types
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Types
5.2.2. Y-o-Y Growth Projections by Types
5.3. Anterior Uveitis Treatment Market Size and Volume Forecast by Types
5.3.1. Corticosteroids
5.3.2. Cycloplegic Agents
5.3.3. Anti-TNF Agents
5.3.4. Immunosuppressants
5.4. Absolute $ Opportunity Assessment by Types
5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global Anterior Uveitis Treatment Market Analysis and Forecast by Region
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Region
6.2.2. Y-o-Y Growth Projections by Region
6.3. Anterior Uveitis Treatment Market Size and Volume Forecast by Region
6.3.1. North America
6.3.2. Latin America
6.3.3. Europe
6.3.4. Asia Pacific
6.3.5. Middle East and Africa (MEA)
6.4. Absolute $ Opportunity Assessment by Region
6.5. Market Attractiveness/Growth Potential Analysis by Region
6.6. Global Anterior Uveitis Treatment Demand Share Forecast, 2019-2026
7. North America Anterior Uveitis Treatment Market Analysis and Forecast
7.1. Introduction
7.1.1. Basis Point Share (BPS) Analysis by Country
7.1.2. Y-o-Y Growth Projections by Country
7.2. North America Anterior Uveitis Treatment Market Size and Volume Forecast by Country
7.2.1. U.S.
7.2.2. Canada
7.3. Absolute $ Opportunity Assessment by Country
7.4. North America Anterior Uveitis Treatment Market Size and Volume Forecast by Types
7.4.1. Corticosteroids
7.4.2. Cycloplegic Agents
7.4.3. Anti-TNF Agents
7.4.4. Immunosuppressants
7.5. Basis Point Share (BPS) Analysis by Types
7.6. Y-o-Y Growth Projections by Types
7.7. Market Attractiveness/Growth Potential Analysis
7.7.1. By Country
7.7.2. By Product Type
7.7.3. By Application
7.8. North America Anterior Uveitis Treatment Demand Share Forecast, 2019-2026
8. Latin America Anterior Uveitis Treatment Market Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis by Country
8.1.2. Y-o-Y Growth Projections by Country
8.1.3. Latin America Average Pricing Analysis
8.2. Latin America Anterior Uveitis Treatment Market Size and Volume Forecast by Country
8.2.1. Brazil
8.2.2. Mexico
8.2.3. Rest of Latin America
8.3. Absolute $ Opportunity Assessment by Country
8.4. Latin America Anterior Uveitis Treatment Market Size and Volume Forecast by Types
8.4.1. Corticosteroids
8.4.2. Cycloplegic Agents
8.4.3. Anti-TNF Agents
8.4.4. Immunosuppressants
8.5. Basis Point Share (BPS) Analysis by Types
8.6. Y-o-Y Growth Projections by Types
8.7. Market Attractiveness/Growth Potential Analysis
8.7.1. By Country
8.7.2. By Product Type
8.7.3. By Application
8.8. Latin America Anterior Uveitis Treatment Demand Share Forecast, 2019-2026
9. Europe Anterior Uveitis Treatment Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.1.3. Europe Average Pricing Analysis
9.2. Europe Anterior Uveitis Treatment Market Size and Volume Forecast by Country
9.2.1. Germany
9.2.2. France
9.2.3. Italy
9.2.4. U.K.
9.2.5. Spain
9.2.6. Russia
9.2.7. Rest of Europe
9.3. Absolute $ Opportunity Assessment by Country
9.4. Europe Anterior Uveitis Treatment Market Size and Volume Forecast by Types
9.4.1. Corticosteroids
9.4.2. Cycloplegic Agents
9.4.3. Anti-TNF Agents
9.4.4. Immunosuppressants
9.5. Basis Point Share (BPS) Analysis by Types
9.6. Y-o-Y Growth Projections by Types
9.7. Market Attractiveness/Growth Potential Analysis
9.7.1. By Country
9.7.2. By Product Type
9.7.3. By Application
9.8. Europe Anterior Uveitis Treatment Demand Share Forecast, 2019-2026
10. Asia Pacific Anterior Uveitis Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Asia Pacific Average Pricing Analysis
10.2. Asia Pacific Anterior Uveitis Treatment Market Size and Volume Forecast by Country
10.2.1. China
10.2.2. Japan
10.2.3. South Korea
10.2.4. India
10.2.5. Australia
10.2.6. Rest of Asia Pacific (APAC)
10.3. Absolute $ Opportunity Assessment by Country
10.4. Asia Pacific Anterior Uveitis Treatment Market Size and Volume Forecast by Types
10.4.1. Corticosteroids
10.4.2. Cycloplegic Agents
10.4.3. Anti-TNF Agents
10.4.4. Immunosuppressants
10.5. Basis Point Share (BPS) Analysis by Types
10.6. Y-o-Y Growth Projections by Types
10.7. Market Attractiveness/Growth Potential Analysis
10.7.1. By Country
10.7.2. By Product Type
10.7.3. By Application
10.8. Asia Pacific Anterior Uveitis Treatment Demand Share Forecast, 2019-2026
11. Middle East & Africa Anterior Uveitis Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Middle East & Africa Average Pricing Analysis
11.2. Middle East & Africa Anterior Uveitis Treatment Market Size and Volume Forecast by Country
11.2.1. Saudi Arabia
11.2.2. South Africa
11.2.3. UAE
11.2.4. Rest of Middle East & Africa (MEA)
11.3. Absolute $ Opportunity Assessment by Country
11.4. Middle East & Africa Anterior Uveitis Treatment Market Size and Volume Forecast by Types
11.4.1. Corticosteroids
11.4.2. Cycloplegic Agents
11.4.3. Anti-TNF Agents
11.4.4. Immunosuppressants
11.5. Basis Point Share (BPS) Analysis by Types
11.6. Y-o-Y Growth Projections by Types
11.7. Market Attractiveness/Growth Potential Analysis
11.7.1. By Country
11.7.2. By Product Type
11.7.3. By Application
11.8. Middle East & Africa Anterior Uveitis Treatment Demand Share Forecast, 2019-2026
12. Competition Landscape
12.1. Global Anterior Uveitis Treatment Market: Market Share Analysis
12.2. Anterior Uveitis Treatment Distributors and Customers
12.3. Anterior Uveitis Treatment Market: Competitive Dashboard
12.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
12.4.1. Santen Pharmaceutical Co. Ltd.
12.4.2. AbbVie Inc.
12.4.3. Novartis AG
12.4.4. Eyegate Pharmaceuticals Inc.
12.4.5. Aldeyra Therapeutics Inc.
12.4.6. Aciont Inc.
12.4.7. Clearside Biomedical Inc.
12.4.8. Sirion Therapeut
Segments Covered in the Report
The global anterior uveitis treatment market has been divided based on treatment types, distribution channels, and regions.
By Treatment Types
The global anterior uveitis treatment market has been divided based on treatment types, distribution channels, and regions.
By Treatment Types
- Corticosteroids
- Cycloplegic Agents
- Anti-TNF Agents
- Immunosuppressants
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- North America
- Europe
- Latin America
- Asia Pacific
- Middle East & Africa
- Santen Pharmaceutical Co. Ltd.
- AbbVie Inc.
- Novartis AG
- Eyegate Pharmaceuticals Inc.
- Aldeyra Therapeutics Inc.
- Aciont Inc.
- Clearside Biomedical Inc.
- Sirion Therapeutics Inc.
- Lux Biosciences Inc.
- Bausch & Lomb Incorporated
- UCB Biopharma S.P.R.L.
- EyePoint Pharmaceuticals Inc.
- Alimera Sciences Inc.
- Regeneron Pharmaceuticals
Key players in the global anterior uveitis treatment market includes Santen Pharmaceutical Co., Ltd., AbbVie Inc., Novartis AG, Eyegate Pharmaceuticals, Inc., Aldeyra Therapeutics, Inc., Aciont Inc., Clearside Biomedical, Inc., Sirion Therapeutics, Inc., Lux Biosciences, Inc., Bausch & Lomb Incorporated, UCB Biopharma S.P.R.L., EyePoint Pharmaceuticals, Inc., Alimera Sciences Inc., and Regeneron Pharmaceuticals.
Collaborations, mergers, acquisitions, agreements, and partnerships are strategies adopted by these players to strengthen their geographical presence.
Our Clients
Related Reports
Some other reports from this category!
